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Abstract
Background: Spinal muscular atrophy (SMA) is an autosomal recessive hereditary disorder caused
by mutations of the survival motor neuron 1 (SMN1) gene. Recently, high-resolution DNA melting
analysis (HRMA) with saturation LC Green dyes has become a powerful post-PCR technique for
genotyping or mutation scanning. So far, no studies have applied HRMA to the molecular analysis
of SMA.
Methods: The exon 7 and the flanking area of the SMN1 and SMN2 genes of 55 SMA patients and
46 unrelated normal individuals were amplified with asymmetric PCR with unlabeled probe and
symmetric PCR without probe, respectively. The saturation LC Green dyes were added to the PCR
system. The PCR products were loaded onto the LightScanner system and were melted from 60°C
to 95°C slowly. The melting curves were acquired and analyzed by the LightScanner software.
Results: Three types of melting curves that correlated with the presumed genotype of SMA
patients and controls were clearly separated on the HRMA chromatogram with the unlabeled
probe. The 55 SMA patients and 46 non-SMA controls were identified with HRMA with a 100%
clinical sensitivity.
Conclusion: The HRMA with saturation LC Green dyes and unlabeled probe appears to be a
suitable, alternative method for the diagnosis of SMA, with high sensitivity and specificity.
Background
Spinal muscular atrophy (SMA) is a common autosomal
recessive hereditary disease characterized by degeneration
of the anterior horn α-motor neurons in the spinal cord,
leading to paralysis and atrophy of proximal muscles. The
survival motor neuron (SMN) gene is the disease-causing
gene of SMA [1], and it exists as two nearly identical cop-
ies, SMN1 and SMN2. SMN1 is the critical gene involved
in SMA, as more than 90% of SMA patients have SMN1
exon 7 homozygous deletions [1-3]. Homozygous
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absence of SMN2 genes does not cause SMA and is found
in about 5% of normal individuals. In SMA patients, the
number of SMN2 copies is inversely correlated with dis-
ease severity [4-6]. Only five nucleotides differ between
SMN1  and  SMN2.  SMN1  can be distinguished from
SMN2 by two nucleotide changes in exon 7 and 8, which
can be used to detect the deletion of SMN1 and establish
the diagnosis of SMA. To date, four assays have been
described for detecting the absence of SMN1: single-
stranded conformation polymorphism (SSCP), restriction
enzyme digestion analysis, denaturing high-performance
liquid chromatography (DHPLC) analysis and liquid
microbead arrays. SSCP is a very time-consuming proce-
dure [1,3]. Restriction enzyme digestion analysis is the tra-
ditional method for SMA, but its accuracy can be hindered
by incomplete digestion [2]. DHPLC is a more recent tech-
nology for SMN1 mutation screening [7-9], but it is con-
fined to the WAVE Nucleic Acid Fragment Analysis
System. While the liquid microbead arrays is a sensitive,
high-throughput approach that can be used to detect
SMN1 exon 7 deletions from blood spots, the cost may
prohibit its application in many laboratories [10].
High-resolution DNA melting analysis (HRMA) with sat-
uration LC Green dyes is becoming a powerful post-PCR
technique for genotyping and mutation scanning. Appar-
ent advantages of HRMA include speed of analysis and
convenience, as there is no need for processing or separa-
tion of PCR products. Recent reports indicate that the sen-
sitivity and specificity is 100% for amplicons less than 400
bp, and those for amplicons between 400 to 1000 bp are
96.1% and 99.4%, respectively [11]. In this report, we
present the results of a study using the HRMA method to
analyze a cohort of SMA patients and controls. To date,
there have been no reports using the HRMA method for
the molecular analysis of SMA.
Methods
Subjects
A total of 55 unrelated patients with SMA and 46 unre-
lated normal individuals were recruited from April 2005
to April 2008. All of the patients fulfilled the diagnostic
criteria [12] and were confirmed to have SMN1 exon 7
homozygous deletions by RFLP and DHPLC analysis
using the detailed procedure previously described
[9,13,14]. Of the 46 normal controls analyzed by RFLP, 3
were homozygous for SMN2  exon7 deletions. The
remaining 43 normal controls possessed both SMN1 and
SMN2. Furthermore, 12 of the normal individuals were
analyzed by real-time fluorescence quantitative PCR, as
previously reported [6,15]. Informed consent was
obtained from each individual or parents of individuals
younger than 18 years. The study was approved by the
local ethics commission. Genomic DNA was isolated
from peripheral blood lymphocytes using the QIAamp
DNA Blood Minikit (QIAGEN, Hilden, Germany).
Asymmetric and symmetric PCR
The exon 7 and flanking area of the SMN1 and SMN2
genes were amplified by PCR, the primers were SMNF(5'-
AGACTATCAACTTAATTTCTGATCA-3') and SMNR(5'-
GATTCACTTTCATAATGCTGG-3'). The length of the PCR
product was 241 base pair and contained 2 nucleotide dif-
ferences between SMN1 and SMN2. For asymmetric PCR,
the 20 μL reaction contained 40 ng of genomic DNA, 200
μM dNTPs, 1.25 U Taq DNA polymerase (Dichuan Biosys-
tem, China), 2.0 ul LCGreen Plus dye (Idaho Technol-
ogy), 0.05 μM SMN F primer and 0.5 μM excess SMN R
primer, and 0.5 μM unlabeled probe to SMN1. The
sequence of the SMN1 probe is 5'-TATAGCTATCTATGTC-
TATATAGCTAT-P-3', in which the underlined "G" is spe-
cific to SMN1  and "-P" indicates a 3' phosphate. For
symmetric PCR, the reaction was similar to that of asym-
metric PCR except that both the SMNF and SMNR primers
were 0.5 μM, and the SMN1 probe was absent. The PCR
reactions were performed in a 9700 Thermal Cycler
(Applied Biosystems, Foster City, CA); the conditions
included an initial denaturation at 94°C for 2 min, fol-
lowed by 45 cycles of 94°C for 30 s, 57°C for 30 s, and
72°C for 30 s and a final extension at 72°C for 5 minutes.
Melting curve acquisition and analysis
The PCR products were transferred to a 96-well plate and
put on the LightScanner (Idaho Technology). The samples
were first denatured at 95°C and rapidly cooled to 40°C
at a rate of 20°C/s, then melted from 60°C to 95°C with
a slope of 0.1°C/s. The data was acquired every 1°C for a
total of 25 readings. Melting curves were analyzed with
LightScanner software (Idaho Technology Inc).
Results
HRMA with unlabeled probe
As illustrated in Figure 1A, HRMA displayed three types of
melting curve shapes that correlated with the genotype of
all the patients and controls. Samples from 55 SMA
patients with a confirmed diagnosis of SMN1 exon 7
homozygous deletion had a lower melting temperature
due to deletion of SMN1 (only possessing SMN2), induc-
ing the probe-target mismatch. The three individuals with
SMN2  deletion (only possessing SMN1) had a higher
melting temperature, because PCR products were perfectly
paired to the unlabeled probe. Melting curves of the con-
trol samples with SMN1 and SMN2 genes showed both
duplexes. On the other hand, the results showed no corre-
lation between the height or area of the curves and the
copy number of the SMN1 or SMN2 gene as determined
by real-time fluorescence quantitative PCR.BMC Medical Genetics 2009, 10:45 http://www.biomedcentral.com/1471-2350/10/45
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HRMA without probe
Melting curve profiles of HRMA without probes were
available for 6 SMA patients with SMN1 deletion, 3 indi-
viduals with SMN2 deletion, and 6 normal controls with-
out SMN1 or SMN2 deletion. It was easy to identify the
controls with SMN1 and SMN2 genes according to the
melting curve shape, while it was difficult to distinguish
patients with a SMN1 deletion from normal individuals
with a SMN2 deletion (Figure 1B).
Discussion
As already reported, SSCP, restriction enzyme digestion
analysis, DHPLC and liquid microbead arrays could be
used in detecting the absence of SMN1; all of these meth-
ods have advantages and disadvantages. Previously, one
study showed that HRMA was superior to DHPLC in
mutation scanning [16]. In the present study, we per-
formed HRMA with and without an unlabeled probe for
the SMA patients and controls. The exon 7 and flanking
area of SMN gene were amplified. There are 2 nucleotide
differences between SMN1 and SMN2 within this 241 bp
product, which correspond to position intron6(-45) (G =
SMN1, A = SMN2) and another to exon 7(+6) (C = SMN1,
T = SMN2) [17]. According to a previous report [18], the
unlabeled probe was designed to target SMN1, contained
the intron6 (-45) difference in the center and was phos-
phorylated at the 3' end to prevent polymerase extension
during amplification. Asymmetric PCR was applied to
improve the rate of hybridization, and the primer ratio of
1:10 referred to in the previous report [18]. The symmetric
PCR was performed routinely. Melting transitions were
monitored in the presence of LCGreen I, a saturated dye
originally designed to detect heteroduplexes [19]. The
results showed three types of melting curve that correlate
to the presumed genotype (SMN1, SMN2, SMN1/SMN2)
were clearly separable on the chromatogram of HRMA
with an unlabeled probe, and we succeeded in distin-
guishing the 55 SMA cases from the controls without any
error. However, the results of the HRMA without the unla-
beled probe were not as good as those with the probe, as
it was difficult to distinguish patients with the SMN1 dele-
tion from normal individuals with the SMN2 deletion.
HRMA with an unlabeled probe has many advantages in
detecting the deletion of SMN1  compared with SSCP,
restriction enzyme digestion analysis, DHPLC and liquid
microbead arrays. First, HRMA is sensitive and accurate:
the 55 patients with SMN1 exon 7 homozygous deletions
were detected by HRMA with 100% sensitivity and specif-
icity in accordance with a previous report using this tech-
nology [11]. Second, HRMA is easy and rapid to perform,
with only four requirements: PCR, saturation LC Green
dyes, unlabeled probe and melting instrumentation. Melt-
ing analysis can be finished within several minutes.
Conclusion
HRMA with saturation LC Green dyes and an unlabeled
probe seems to be a useful alternative strategy for the diag-
nosis of SMA. This study has provided "proof of principle"
data indicating the utility and sensitivity of HRMA when
applied to diagnostic testing for SMA. However, our find-
ings should be replicated in a much larger sampling of
SMA patients to assess the specificity and sensitivity.
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